A 2025 study demonstrated that AI-driven design tools can reduce the time required to engineer functional genetic circuits from months to weeks, a leap that has sparked both excitement and unease among researchers. This acceleration,
Listen to this article0:00/01× The validation of Permutation Entropy (PeEn) and Entropy of Difference (EoD) as statistically equivalent to the proprietary Bispectral Index (BIS) marks a pivotal shift in how we monitor patient
Listen to this article0:00/01× On July 14, 2026, the scientific community marked a definitive pivot in how we approach human longevity, moving beyond the management of age-related symptoms to the direct correction of
Listen to this article0:00/01× The most counter-intuitive finding in contemporary longevity research is that the field's most celebrated mechanism for reversing aging currently lacks any empirical confirmation of its efficacy. While
0:00 /0:00 1× Listen to this article0:00/01× Five years ago, the narrative surrounding CRISPR/Cas9 was dominated by its capacity as a precise "molecular scalab," a tool designed primarily
The most laborious part of a gene-editing experiment isn't the pipetting—it's the design. For every successful CRISPR experiment, researchers spend weeks navigating a labyrinth of guide RNA selection, delivery method
0:00 /0:00 1× Listen to this article0:00/01× The protein universe is vast—hundreds of millions of sequences, each with a unique three-dimensional fold that determines its function. For decades, biologists have
Listen to this article0:00/01× The longevity therapeutics market has long been a landscape of bold claims and modest data — a field where press releases often outpace peer-reviewed evidence. But today, that landscape gains
CRISPR-Cas9 is reshaping gerontology — new research proves aging markers are not inevitable but reversible, causal targets that can be genetically corrected.
